GS Junior测序系统用于肿瘤个人化治疗研究[创新技巧]

肿瘤个人化治疗成功与否很大程度上取决于其肿瘤基因的突变类型。在德国一个实验室中，罗氏GS Junior测序系统被用于肿瘤个人化治疗研究中，通过对临床治疗相关的外显子DNA进行测序，鉴定肿瘤组织的基因组突变类型，为后续的抗体治疗药物提供用药指导。 

The next-generation GS Junior Sequencing System enables cost effective and comprehensive profiling of all the relevant genes.
 
肿瘤个人化治疗是肿瘤治疗的发展方向，比如使用单克隆抗体，抑制一些蛋白的促肿瘤生长作用。全面而准确评估患者的肿瘤基因背景，是抗体治疗成功的关键。目前这种治疗只针对少数的肿瘤相关基因区域，而使用二代测序仪GS Junior系统能够经济、有效地获得所有这些相关基因的序列信息。与此相比，传统毛细管电泳测序方法，检测灵敏度较低，价格相对较高，尤其是对于肿瘤突变小于20%的情况。

二代测序技术将对肿瘤个人化治疗起到重要作用。GS Junior能够获得肿瘤组织的混合细胞中各种基因突变信息，无论是已知的还是新型的突变。此外，GS Junior在分析复杂的肿瘤样本方面的优势在于它的长读长特点，在可以灵敏检测低频率的体细胞突变的同时，又可以判定各种类型的肿瘤突变，包括大片段的结构变异。

欢迎索取GS Junior系统的更多资料！

Roche´s GS Junior Sequencing System used in research on personalized tumor treatment

Individual tumor treatment success largely depends on the mutation status of tumor genes. Roche’s GS Junior Sequencing system is now used for a sequencing approach that has great potential for personalized medicine: the Center for Human Genetics and Laboratory Medicine Dr. Klein and Dr. Rost, and IMGM Laboratories, both located in Martinsried, Germany, reported using the Roche GS Junior Benchtop System to sequence clinically relevant protein coding DNA (exons) and identify genomic variations in solid tumors treated with an antibody-based medicine.

Personalized tumor treatments, such as monoclonal antibodies (mAb) that specifically target tumor-inducing proteins, require a precise and comprehensive assessment of an individual’s genetic profile for the targeted genes. Current therapies target only a limited region of the relevant tumor genes, whereas the next-generation GS Junior Sequencing System enables cost effective and comprehensive profiling of all the relevant genes. In contrast, conventional capillary sequencing techniques often lack the sensitivity and cost effectiveness to detect tumor mutations occurring at less than 20 percent frequency.

“The future of personalized tumor treatment lies in this sequencing approach,” said Dr. Hanns-Georg Klein, MD, CEO of both IMGM and the Center for Human Genetics. “Through our research, we’ve found that it’s critical to ensure a comprehensive analysis of a tumor variant population, including known and novel mutations.”

These findings underscore the utility of Roche’s GS Junior System for investigating complex tumor samples. The long, accurate sequencing reads are ideal for identifying multiple tumor mutations that can include structural variations and rare somatic mutations.